JP2011519873A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519873A5
JP2011519873A5 JP2011507792A JP2011507792A JP2011519873A5 JP 2011519873 A5 JP2011519873 A5 JP 2011519873A5 JP 2011507792 A JP2011507792 A JP 2011507792A JP 2011507792 A JP2011507792 A JP 2011507792A JP 2011519873 A5 JP2011519873 A5 JP 2011519873A5
Authority
JP
Japan
Prior art keywords
salt
chloro
trimethylpiperazine
phenylindan
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519873A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2009/050107 external-priority patent/WO2009135495A1/en
Publication of JP2011519873A publication Critical patent/JP2011519873A/ja
Publication of JP2011519873A5 publication Critical patent/JP2011519873A5/ja
Pending legal-status Critical Current

Links

JP2011507792A 2008-05-07 2009-05-07 認知欠損を治療する方法 Pending JP2011519873A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200800647 2008-05-07
DKPA200800647 2008-05-07
DKPA200801392 2008-10-03
DKPA200801392 2008-10-03
DKPA200801519 2008-11-04
DKPA200801519 2008-11-04
PCT/DK2009/050107 WO2009135495A1 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Publications (2)

Publication Number Publication Date
JP2011519873A JP2011519873A (ja) 2011-07-14
JP2011519873A5 true JP2011519873A5 (enExample) 2012-06-21

Family

ID=40870955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507792A Pending JP2011519873A (ja) 2008-05-07 2009-05-07 認知欠損を治療する方法

Country Status (15)

Country Link
US (2) US20090306092A1 (enExample)
EP (1) EP2285377A1 (enExample)
JP (1) JP2011519873A (enExample)
KR (1) KR20110021754A (enExample)
CN (1) CN102065861B (enExample)
AU (1) AU2009243813B2 (enExample)
BR (1) BRPI0912223A2 (enExample)
CA (1) CA2722374A1 (enExample)
CO (1) CO6311083A2 (enExample)
EA (1) EA018927B1 (enExample)
IL (1) IL209084A0 (enExample)
MX (1) MX2010012037A (enExample)
NZ (1) NZ589571A (enExample)
WO (1) WO2009135495A1 (enExample)
ZA (1) ZA201007912B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
EA024651B1 (ru) 2011-06-20 2016-10-31 Х. Лундбекк А/С Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20210395208A1 (en) * 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6444854B1 (en) * 1998-05-01 2002-09-03 Chiral Technologies Europe Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
IN187170B (enExample) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
AU2003284899A1 (en) * 2002-10-29 2004-05-25 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
WO2005016901A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TW200640891A (en) * 2005-02-16 2006-12-01 Lundbeck & Co As H Tartrate and malate salts of a pharmarceutical compound
WO2006086985A1 (en) * 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation

Similar Documents

Publication Publication Date Title
JP2011519873A5 (enExample)
JP2011522816A5 (enExample)
JP2011524850A5 (enExample)
JP2016163571A5 (enExample)
JP2009541216A5 (enExample)
JP2012255026A5 (enExample)
HRP20161121T1 (hr) Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost
JP2012515720A5 (enExample)
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2009280621A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2012517449A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
JP2007516193A5 (enExample)
JP2013502446A5 (enExample)
JP2012504560A5 (enExample)
JP2009062388A5 (enExample)
JP2012531402A5 (enExample)
JP2007513993A5 (enExample)
JP2008513510A5 (enExample)
MX2011008336A (es) Derivados de dihidroquinolinona.
JP2018503644A5 (enExample)
JP2017526693A5 (enExample)